Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of pharmacogenetics to optimize immunosuppressive therapy.

Therapeutic drug monitoring - 1 Jun 2010

Macphee Iain A M

Abstract excerpt

Pharmacogenetic strategies offer promise as an adjunct to therapeutic drug monitoring in achieving target blood concentrations of the immunosuppressive drugs as early as possible after transplantation. To date, the only strategy to have been tested in a clinical trial is the use of the cytochrome P450 3A5 (CYP3A5) genotype to predict tacrolimus dose. Other potential candidates are CYP3A5 and sirolimus and UGT1A9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclosporine

Share to Cytochrome P-450 CYP3A

Share to Immunosuppression Therapy

Share to IMP Dehydrogenase

Share to Sirolimus

Share to Tacrolimus

Source

Identifiers

PMID: 20431509
DOI: 10.1097/FTD.0b013e3181dca995

Genes

ABCB1
IMPDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of pharmacogenetics to optimize immunosuppressive therapy.PMID 20431509Read ↗

A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.Semantic proximity Read ↗

Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.Semantic proximity Read ↗

Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted PatientsSemantic proximity Read ↗

Pharmacogenetic biomarkers: cytochrome P450 3A5.Semantic proximity Read ↗

Individualization of immunosuppression: concepts and rationale.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.Semantic proximity Read ↗

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Semantic proximity Read ↗

Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs.Semantic proximity Read ↗

Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapySemantic proximity Read ↗

Personalized immunosuppression after kidney transplantation.Semantic proximity Read ↗

Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?Semantic proximity Read ↗

Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.